In fiscal 2026, which ended Jun 30, 2026, Bio-Techne Corp generated $292.1 million of cash from operations, up 1.6% from the year before. It spent $28.9 million on capital expenditures. That left free cash flow of $263.2 million. The company returned $49.9 million in dividends and $41.7 million in share buybacks to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2013
Jun 30, 2013
|
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | ||||||||||
| Depreciation and amortization |
97
-11.4%
|
110
-1.6%
|
112
+4.2%
|
107
+6.1%
|
101
+15.2%
|
88
+6.1%
|
83
+5.8%
|
78
+21.3%
|
64
+7.4%
|
12
-1.2%
|
| Stock-based compensation |
41
+1.3%
|
41
+7.3%
|
38
-3.0%
|
39
-7.0%
|
42
-13.9%
|
49
+51.3%
|
32
+0.3%
|
32
+14.3%
|
28
+93.0%
|
—
|
| Operating cash flow |
292
+1.6%
|
288
-3.8%
|
299
+17.5%
|
254
-21.8%
|
325
-7.6%
|
352
+71.6%
|
205
+13.0%
|
182
+6.6%
|
170
|
124
-2.5%
|
| Investing | ||||||||||
| Capital expenditures |
29
-7.0%
|
31
-50.7%
|
63
+64.4%
|
38
-14.8%
|
45
+1.4%
|
44
-14.4%
|
52
+103.6%
|
25
+21.4%
|
21
+37.9%
|
22
+273.2%
|
| Investing cash flow |
-18
+48.3%
|
-35
+82.7%
|
-203
+23.6%
|
-266
-174.3%
|
-97
+60.2%
|
-244
-998.7%
|
27
+108.0%
|
-337
-770.0%
|
-39
|
-31
-44.0%
|
| Financing | ||||||||||
| Dividends paid |
50
-0.9%
|
50
-0.1%
|
50
+0.3%
|
50
+0.2%
|
50
+1.1%
|
50
+1.5%
|
49
+1.1%
|
48
+0.8%
|
48
+1.4%
|
43
+6.0%
|
| Stock buybacks |
42
-84.9%
|
276
+244.5%
|
80
+309.2%
|
20
-87.8%
|
161
+272.8%
|
43
-13.8%
|
50
+225.3%
|
15
|
—
|
2
-92.3%
|
| Financing cash flow |
-169
+33.4%
|
-254
-107.4%
|
-122
-641.2%
|
23
+109.3%
|
-243
-288.2%
|
-63
+66.0%
|
-184
-236.8%
|
134
+235.5%
|
-99
|
-45
+30.9%
|
| Change in cash | ||||||||||
| Effect of exchange rate |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-0
+85.3%
|
-2
-522.0%
|
-1
+59.0%
|
| Net change in cash |
103
+886.3%
|
10
+136.1%
|
-29
-459.6%
|
8
+130.2%
|
-27
-150.6%
|
52
+14.7%
|
46
|
—
|
—
|
—
|
| Free cash flow |
263
+2.6%
|
257
+8.7%
|
236
+9.2%
|
216
-22.9%
|
280
-8.9%
|
308
+100.6%
|
153
-1.8%
|
156
+4.5%
|
149
|
101
-16.3%
|
| Per share | ||||||||||
| Free cash flow per share |
1.68
+4.4%
|
1.61
+9.4%
|
1.47
+10.0%
|
1.34
-21.8%
|
1.71
-10.1%
|
1.90
-51.2%
|
3.90
-3.0%
|
4.02
+2.3%
|
3.93
|
2.74
-16.0%
|
| Dividend per share |
0.32
+0.0%
|
0.32
+0.0%
|
0.32
+0.0%
|
0.32
+0.0%
|
0.32
+0.0%
|
0.32
-75.0%
|
1.28
+0.0%
|
1.28
+0.0%
|
1.28
+0.0%
|
1.18
+6.3%
|
| Shareholder returns | ||||||||||
| Returned to shareholders |
92
|
326
|
130
|
70
|
211
|
93
|
99
|
64
|
48
|
45
|
| Share of free cash flow |
34.80%
|
127.12%
|
55.26%
|
32.31%
|
75.31%
|
30.14%
|
64.52%
|
40.82%
|
32.10%
|
44.79%
|
| Ratios | ||||||||||
| Free cash flow margin |
21.66%
|
21.03%
|
20.37%
|
19.02%
|
25.36%
|
33.07%
|
20.78%
|
21.88%
|
23.24%
|
32.56%
|
| Capital expenditures to revenue |
2.37%
|
2.54%
|
5.42%
|
3.36%
|
4.06%
|
4.76%
|
7.00%
|
3.56%
|
3.26%
|
7.23%
|
| Stock-based compensation to revenue |
3.40%
|
3.35%
|
3.28%
|
3.45%
|
3.82%
|
5.26%
|
4.38%
|
4.52%
|
4.39%
|
—
|
| Cash conversion |
1.61x
|
3.92x
|
1.78x
|
0.89x
|
1.24x
|
2.52x
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TECH (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- MN
- Headquarters
- Minneapolis, MN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 842023
- Former names
- TECHNE CORP /MN/ (until Oct 28, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.